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Abstract A metabolomics-based systems toxicology
approach was used to proﬁle the urinary metabolites for the
toxicity related processes and pathogenesis induced by
doxorubicin (DOX) to rats. Endogenous metabolite proﬁles
were obtained with ultra performance liquid chromatogra-
phy-mass spectrometry (UPLC-MS) for rats receiving dif-
ferent single dosages of DOX (5, 10 or 20 mg/kg) prior and
at three time points after dosage. Principal components
analysis (PCA) allowed detection of two major systemic
metabolic changes with the time due to the induced toxicity.
Furthermore, Analysis of variance (ANOVA) Simultaneous
Component Analysis (ASCA) was applied to reveal the
variation caused by time and dose, and their interaction in a
multivariate way. Finally, various metabolites involved in
the toxic processes could be identiﬁed using their accurate
mass and MS
n experiments, and possible mechanisms of the
toxicity of DOX were postulated. In conclusion, meta-
bolomics as a systems toxicology approach was able to
provide comprehensive information on the dynamic process
of drug induced toxicity. In addition, detection of the sys-
temic toxic effects could be obtained with metabolomics at
an earlier stage compared to the clinical chemistry and
histopathological assessment.
Keywords Metabolomics   Doxorubicin   UPLC-MS  
FTMS   Systems toxicology
1 Introduction
The rapid improvements of the technologies enabling the
determination of large numbers of biomolecules and
subsequent multivariate data analysis provide the oppor-
tunity to obtain new insights in the toxicity by a bio-
chemically based systems toxicology approach (Van der
Greef et al. 2007; Van der Greef et al. 2004). In such an
approach, the biochemical changes in preferably easily
accessible biological ﬂuids such as blood or urine are
detected as biomarkers for toxicity-related pathogenesis.
The biomarkers can be mapped onto known biochemical
pathways, and may be then conﬁrmed to correspond to
toxic compound related biochemical processes, or may
suggest new biochemical pathways. Moreover, some bio-
markers may be indirect markers and can only be under-
stood in the perspective of the whole system, offering the
potential opportunity to explore novel biochemistry and
reveal new insights in the toxicity mechanisms. In the
context of systems biology, metabolomics acquires signals
representing tens to hundreds of metabolites in bioﬂuids
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DOI 10.1007/s11306-009-0165-3and enables assessment of toxicity in vivo, providing
rapid, often minimal invasive, robust and reproducible
information about biochemical changes due to toxicity and
has shown particular promise in the area of toxicology as
a systems toxicity approach (Nicholson et al. 1999; Keun
2006; Waters et al. 2005). Extensive research has been
performed by using Nuclear Magnetic Resonance (NMR)
to investigate the mechanisms, site and severity of toxic
effects of model toxins (Lindon et al. 2003). Because of
the high sensitivity, electrospray mass spectrometry,
especially coupled with liquid chromatography, has
emerged as a complementary technique for generating
metabolomics data and has been applied to different bio-
ﬂuids (urine, plasma, synovial ﬂuid) and a wide scope of
metabolites (Kamphorst et al. 2007; Lafaye et al. 2003;
Yang et al. 2006; Lenz et al. 2004; Williams et al. 2005).
Ultra performance liquid chromatography (UPLC)
employs porous particles with internal diameters smaller
than 2 lm, resulting in higher peak capacity, improved
resolution and increased sensitivity compared to conven-
tional HPLC columns, therefore making it even more
suitable for a metabolomics approach (Theodoridis et al.
2008).
Doxorubicin (DOX, Fig. 1e) is a topoisomerase II poison
and widely used in the treatment of various human neo-
plasms(SingalandIliskovic1998;DeBeeretal.2001;Swift
et al. 2006). However, the clinical use of DOX is limited by
the development of a dose-dependent cumulative cardio-
toxicity (Singal and Iliskovic 1998; De Beer et al. 2001).
Furthermore,animalstudiesrevealpotentialliverandkidney
lesions. It was reported that DOX could induce hepatic lipid
peroxidation (Bagchi et al. 1995) and changes in the kidney
of rats including increases of glomerular capillary perme-
ability and tubular atrophy (Wapstra et al. 1999; Saad et al.
2001). The exact causal mechanisms of DOX induced tox-
icity remain unclear and various mechanisms have been
proposed to interpret the toxicity, including inhibition of
nucleic acid and protein synthesis (Meliksetian et al. 1997),
direct interaction with the actin–myosin contractile system,
anthracycline metabolite hypothesis, alterations in platelet-
activatingfactor,prostaglandinandintracellularcalciumetc.
(DeBeeretal.2001).Mostoftheevidencesindicatethatfree
radicals are involved (De Beer et al. 2001; Kalender et al.
2005; Oliveira et al. 2004). In this study, we applied a non-
invasive, sensitive UPLC-MS based urine metabolite proﬁle
approach to investigate the lesions induced by DOX. The
purpose was to investigate the systemic toxic processes of
DOXinducedtoxicitiesincludingonsetandprogression,and
the potential mechanisms involved. For this, pattern-recog-
nition algorithms principal components analysis (PCA) and
ANOVA simultaneous component analysis (ASCA) were
used to ﬁnd systemic metabolic changes with time, dose and
Fig. 1 Full-scanUPLC-MSmetaboliteproﬁlesofurinesamplesofthe
same rat of the middle dose a 24 h before administration and b 24, c 48
andd96 hafteradministrationofDOX.Theinseteshowsthestructure
of DOX, which is detected in urine after administration at 14.7 min.
Theinset fshows a typical mass spectrum ofthe chromatographic peak
with a retention time of 16.7 min. The inset g is the enlarged
chromatogram from 0 to 14 min of d. All chromatograms are
normalized on the intensity of the highest peak
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123their interaction. In addition, the identity of potential bio-
markers found had to be revealed to allow interpretation.
2 Methods
2.1 Chemicals
Doxorubicin hydrochloride was obtained from ShangHai
Hualian Pharmaceuticals (Shanghai, China; batch No.
040502), and diluted with 0.9% (w/v) saline to a concen-
tration of 1.25 mg/ml, 2.5 mg/ml and 5 mg/ml for intra-
peritoneal injection. Chemicalstandards suchascholicacid,
hippuric acid, uric acid and 2,8-quinolinediol were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Aceto-
nitrile, HPLC grade, was purchased from Fisher Scientiﬁc
(Loughborough, UK). Formic acid (HPLC/SPECTRO
grade) was purchased from Tedia (Fairﬁeld, OH, USA).
Water was produced by a Milli-Q Ultra-pure water system
(Millipore, Billerica, USA). Leucine-enkephalin and
b-glucuronidase were obtained from Sigma-Aldrich (St.
Louis, MO, USA).
2.2 Animals treatments and samples collection
Male Wistar rats weighing 280–320 g were obtained from
Beijing National Medicine Evaluation Center (Beijing,
China). The rats were housed under controlled humidity
(35–50%) and temperature (20–25C) with a 12 h light/
dark cycle. Animals had free access to certiﬁed rodent
chow (National Medicine Evaluation Center, Beijing,
China) and water.
For metabolomics, a total of 20 rats were randomly
divided into four groups with ﬁve rats in each group, i.e.
control, low, middle and high dose group, and housed in
metabolism cages. The rats of low, middle and high dose
group received a single dose of 5 mg/kg, 10 mg/kg and
20 mg/kg DOX intraperitoneally. The control group
received a single dose of the same volume of 0.9% (w/v)
saline. Urine samples were collected over ice during 24 h
before administration (-24 h) and 0–24 h, 24–48 h and
72–96 h after dosing. Urine samples were centrifuged
(3,0009g, 10 min) and the supernatants were stored at
-80C until analysis.
For clinical chemistry and histopathology, 60 rats were
grouped and dosed as above (15 animals per group). Five
rats were selected from each group randomly and sacriﬁced
at 24, 48 and 96 h after administration. The plasma samples
were analyzed by standard clinical chemistry methods using
a Hitachi 7020 Automatic Analyzer (Hitachi, Tokyo, Japan)
for aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), creatine kinase (CK), creatinine (CREA),
blood urea nitrogen (BUN) and lactate dehydrogenase
(LDH) (Saad et al. 2001). Signiﬁcant changes compared to
the control group in these parameters were determined
using a Student’s t-test (Microsoft Excel version 2002). The
target organs, i.e. heart, liver and kidney,were processed for
parafﬁn sectioning, stained and examined using light
microscopy.
2.3 Sample preparation
Prior to analysis, the urine samples were thawed at room
temperature and centrifuged under 10,000g for 5 min. The
supernatant was diluted with water in the ratio of 1:4 (v/v).
2.4 Chromatography
Chromatographic separations were performed on a
100 9 2.1 mm ACQUITY-1.7 lm C18 column (Waters
Corp, Milford, USA) using an ACQUITY-Ultra Perfor-
mance Liquid Chromatography system (Waters). A
‘‘purge-wash-purge’’ cycle was employed on the auto-
sampler, with 80% aqueous methanol as the wash solvent
and 10% aqueous methanol as the purge solvent to ensure
that the carry-over between injections was minimized.
The column was maintained at 35C and a gradient of
0.1% aqueous formic acid (solvent A) and acetonitrile
(solvent B) used as follows: a linear gradient from 0% to
25% solvent B in 14 min, subsequently a linear gradient
from 25% to 100% B in 4 min, and then 100% B kept for
1.5 min. Next, the solvent was returned to 100% A within
0.1 min and the system equilibrated for 1.5 min. The ﬂow
rate was 0.35 ml/min and a 5 ll aliquot of each sample was
injected onto the column. Each sample was analyzed in
duplicate. The eluent was introduced to the mass spec-
trometry directly, i.e. without a split.
2.5 Mass spectrometry
MassspectrometrywasperformedonaMicromassoa-Q-Tof
(Waters MS Technologies, Manchester, UK). The desolva-
tiongaswassetto500 l/hatatemperatureof350C,thecone
gas to 50 l/h and the source temperature to 100C. The
capillaryvoltagewassetat2,900 Vinpositiveionmodeand
2,600 Vinnegativeionmode,andtheconevoltagewassetat
35 V. The data acquisition rate was set to 0.4 s/scan, with a
0.1 s interscan delay. For accurate mass acquisition, a lock-
mass of leucine enkephalin at a concentration of 2 ng/lli n
methanol/1% aqueous acetic acid (50/50 v/v) was used via a
locksprayinterfaceataﬂowrateof10 ll/minmonitoringfor
positive ion mode ([M ? H]
? = 556.2771) and negative
mode([M - H]
- = 554.2615). Data were collected in
centroid mode from 50 m/z to 850 m/z with a lockspray
Systems toxicology study of doxorubicin on rats 409
123acquisition of 1 s every 20 s, and the lock mass data were
averaged over 10 scans for correction.
2.6 Data processing, multivariate analysis
and biomarker identiﬁcation
The LC-MS data were analyzed using the Micromass
MarkerLynx Applications Manager (Version 4.0, Waters,
UK). An ApexTrack- peak detection algorithm was used in
MarkerLynx to detect peaks and align retention times of
the peaks for all chromatograms. The data were combined
into a single data matrix by aligning peaks with the same
mass/retention time pair together from each data ﬁle in the
dataset, along with their associated intensities. The differ-
ences in concentration of compounds between individual
urine samples are compensated by peak normalization. The
intensities of the peaks were normalized so that the sum of
the intensities of all peaks of a single LC-MS run were
equal between different runs. The intensities of each peak
of two duplicate injections were averaged and the ﬁnal
dataset consisted of 80 (20 9 4) samples. Peaks derived
from DOX and its possible metabolites were excluded from
the dataset. DOX in urine samples was excluded by the
comparison of retention time and MS spectrum of DOX
chemical standard. If a peak was only detected in the
samples after dose, then metabolynx (Version 4.0, Waters,
U.K.) was used to ﬁnd if it was a possible metabolite of
DOX by the differences in mass that can be attributed to
metabolic transformation such as loss of methyl, addition
of oxygen or a conjugate. With above described method,
two datasets were constructed, the ﬁrst dataset included the
peaks from 0.5 min to 14 min and the second dataset
included the peaks from 0.5 min to 18 min.
The resulting dataset comprising peak numbers (RT—
m/z pair), sample names, and ion intensities was analyzed
by PCA and ASCA in MATLAB (version R2006b, The
Mathworks, Natick, MA).
Identiﬁcation of potential biomarkers was based on
online and off-line LC-MS techniques. The accurate
mass determinations was performed by online UPLC-oa-
Q-Tof with lockspray or by fraction collection of the LC
eluent and determined with a linear-ion trap-Fourier-
transform ion cyclotron resonance mass spectrometer
(LTQ-FTMS, Thermo Fisher, San Jose, CA, USA) by
direct infusion experiments. MS
2 spectra were generated
with Micromass oa-Q-Tof and MS
3 spectra were gener-
ated with QSTAR (Pulsar i, PE/Sciex, Canada) and LTQ-
FTMS for identiﬁcation of 2,8-quinolinediol glucuronic
acid conjugate. Finally, the provisionally identiﬁcations
of metabolites were validated with authentic chemical
standards by comparison of the retention times and MS/
MS spectra. The identiﬁcation of the glucuronic acid
conjugate involved enzyme degradation. The appropriate
fraction of the LC eluent containing glucuronic acid
conjugate was freeze dried and subsequently incubated
with b-glucuronidase solution for 12 h (pH 4.7, 37C).
Next, acetonitrile was added in the ratio of 4:1 (v/v) and
mixed for 5 min and subsequently centrifuged under
10,000 g for 5 min. The supernatant was collected for
LC-MS analysis.
The interaction and pathway analysis of potential bio-
markers was performed with Metacore version 4.3 (Gene-
Go Inc, St Joseph, MI). Network interaction analysis was
performed on the basis of ‘shortest paths’ and the number
of steps in a path were 4.
3 Results and discussion
3.1 Clinical chemistry and histopathological
assessment
Various clinical parameters were measured in plasma in
order to monitor the toxicity effects of DOX (Table 1).
Actually, in the high dose group (DOX applied at 20
mg/kg), the concentration of ALT and AST showed sig-
niﬁcant increase in blood 24 h after administration; ALT,
AST and CK increased 48 h after dosing, and ﬁnally all
parameters changed signiﬁcantly 96 h after dosing. How-
ever, these clinical parameters did not show a signiﬁcantly
change for the different time points at the middle (10 mg/
kg) and low (5 mg/kg) dose, only for LDH a statistically
signiﬁcant change could be observed 96 h after dosing for
the middle dose group.
With histopathological examination no signiﬁcant
changes in liver, kidney and heart in all groups were
detected 24 h after administration of DOX. Forty-eight
hours after administration, toxicity-related alterations
including mild myocardial ﬁbers swelling, liver cell
hydropic degeneration and kidney tubules swelling were
observed in the high dose group; in the middle-dose group
there were no changes observed in hearts but mild swelling
and hydropic degeneration was found in livers and kidneys,
whereas no changes were observed in the low dose group.
Ninety-six hours after administration, in the high dose and
middle dose groups distinct organ-lesions were observed
including interstitial oedema, subendocardial ﬁbrosis and
degeneration of the myocardium in hearts, centrilobular
hepatocellular necrosis and vacuolation in livers and
tubular necrosis, large hyaline casts in tubular lumen,
cloudy swelling of the tubular degeneration, tubular dila-
tation glomerular congestion in the kidneys, whereas in the
low dose group no changes were observed. The clinical
chemistry and histopathology indicated the presence of
dose and time dependent lesions to liver, heart and kidney
due to the toxicity of DOX.
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1233.2 UPLC-MS
In this study a simple urine proﬁling method was aimed for
rather than a prefractionation of urine and subsequent
analysis of the various fractions. Therefore, for sample
preparation the sample was only diluted with water, and
analyzed with UPLC-MS using a linear gradient with 0.1%
formic acid and acetonitrile as eluents. As more metabo-
lites were detected in positive mode than with negative
mode, positive mode was chosen in this study. Typical
total ion chromatograms of rat urines (Fig. 1) showed
information rich metabolite proﬁles; totally more than
2,700 chromatographic peaks could be detected in the
various ion traces (after administration, DOX can be
detected in urine sample with retention time of 14.7 min
Fig. 1e). Metabolite proﬁles of post-dose urine obtained by
UPLC-MS revealed signiﬁcant metabolic alterations,
especially 96 h after administration, a group of metabolites
with retention times from 14 min to 18 min were signiﬁ-
cantly higher in the samples of the high and middle dose
groups (Fig. 1a–d).
3.3 Multivariate data analysis
The data were analyzed using PCA to obtain a global view
and to ﬁnd the systemic metabolic changes with time and
dose. Ninety-six hours after administration the metabolites
with retention times from 14 min to 18 min were signiﬁ-
cantly higher in the high and middle dose samples (Fig. 1).
First, the peaks of whole chromatogram (0.5–18 min) were
used to construct a dataset for PCA analysis; it was found
that the peaks eluting from 14 min to 18 min tend to have a
dominant effect in the PCA analysis. To investigate this
further, the peaks of the whole chromatogram were sepa-
rated into two parts, the ﬁrst part was from 0.5 min to
14 min, the second part was from 14 min to 18 min; and
both datasets were subjected to PCA analysis. A better
separation of groups according to time and dose was
obtained by using the peaks acquired from 0.5 min to
14 min. Principal components 1 (PC1) and 2 (PC2)
explained 40% and 20% of the total variance (Fig. 2). The
urine samples that were collected prior to administration of
DOX and the control samples were clustered together in the
PCA scores plot, together with the low-dose group samples
24 h and 48 h after applying DOX. All remaining samples
were separated from the control and prior dose samples.
Compared with the clinical chemistry and histopathological
assessment, the metabolomics approach provided a more
sensitive method to detect effects of toxicity; for example,
whereas there was no clear difference between the middle
dose group at 24 and 48 h after administration for the
clinical parameters compared to the control group, a dif-
ference between especially the middle dose group at 48 h
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123and control group, but also to some extent between the
middle dose group at 24 h and control group, was visible
with the PCA score plot. For the middle dose group (and
also high dose group) at 24 h, a difference was found with
the PCA score plot compared to the control group, but not
with the histopathological assessment. Fig. 2 showed that
due to the toxicity of DOX, after dosing the metabolite
proﬁles of dosed rats were different form that of undosed
rats.
The toxicity effects induced by DOX are dose and time
dependent (Singal and Iliskovic 1998; De Beer et al. 2001).
Figure 2 shows that the high dose group shows a larger
response on DOX, i.e. a larger deviation from the control
group and prior administration group, than the middle and
low dose groups for each time point after dosing. Two
different trends of the samples with time in the PCA score
plot could be observed: 24 h and 48 h after dosing a shift
of all middle and high dose samples from the control and
prior dosing samples towards the right upper quarter can be
observed, which was highest for the high dose samples;
96 h after dosing, there was an additional shift superim-
posed towards the lower right quarter observed, which was
again highest for the high dose and lowest for the low dose.
Such a path of samples in the PCA score plot with time
may be considered as a metabolic trajectory (Keun et al.
2004) and describes a systemic metabolic change (Keun
et al. 2004; Holmes et al. 1992; Beckwith-hall et al. 1998).
There was no trend to recover from the dose effect,
which might suggest that the induced lesion was irrevers-
ible. These results were conﬁrmed by histopathology,
where multiple organs necroses were observed at 96 h post
dose, and to some extent at 48 h. The DOX induced
toxicity might be interpreted to have a ‘‘time threshold’’:
for the low-dose group, from the PCA scores plot there was
no separation after 24 and 48 h compared with the control
group, only after 96 h, differences were observed. This
result suggests that even a low dose of DOX still can cause
toxicity effects, but the effect is expressed in the samples
only after some time. The results of PCA analysis suggest
that the toxicity effects of DOX are dose and time depen-
dent, however, the different variations due to time and
dose, and their possible interaction are difﬁcult to separate
using PCA.
To separate the dose and time effects and estimate
whether the dose effect depends on the time (i.e. interaction
effect between dose and time), ASCA was used. ASCA
splits the original dataset into different datasets describing
the main dose effect, main time effects and a dose-time
interaction (Eq. 1) (Smilde et al. 2005; Jansen et al. 2005).
Xoriginal ¼ Xdose þ Xtime þ Xdosetime þ Xresidual ð1Þ
By separating the original dataset into several sub-
datasets, submodels can be constructed to elucidate time,
dose and time-dose interaction effects of administrating
DOX to the rats. As for PCA, for ASCA only the peaks with
retention times between 0.5 and 14 min were taken into
account. It was found that the amount of variation related to
time, dose and their interaction were 30%, 12% and 23%,
respectively. The residual variation was 35%. This result
indicates that time, dose and their interaction all contributed
to the development of DOX induced toxicity and the
variation related to time was dominant. Further, it would be
helpful to investigate the ‘pure’ effect of dose, time or their
interaction on the metabolite proﬁles. PC1 of the submodel
for ‘dose’ (Fig. 3a) explained 86% of the variation on the
factor of ‘dose’ and showed an increasing separation of low,
middle to high-dose from the control group. Similar results
were also found for the submodel for ‘time’, an increasing
separation from 24 h before dosing was found according to
24 h, 48 h and 96 h after administration, in which PC1
explained 72% of the variation (Fig. 3b). The plots of PC1
over dose and time showed in both cases an increase of PC1
with dose or time, which indicated that the impact of DOX
on the metabolite proﬁles increased with the dose and time
(Fig. 3a, b). Investigation of the interaction model (the
‘dose 9 time’ model) (Fig. 3c) revealed the additional
effects of DOX on top of the pure dose and time models.
Clearly the time and dose effects were not independent of
each other. The submodel of ‘dose 9 time’ accounted for
23% of original variation and PC1 explained 45% of the
variation of the submodel. For the control, low-dose and
middle-dose samples similar and rather constant patterns
over time were observed; only the 96 h samples seemed to
be slightly different from the previous time point samples.
On the other hand, for the high-dose samples a different
Fig. 2 PCA score plot of the urine samples analyzed by UPLC-MS of
the four different dose-groups at the four different time points.
Assignment of the colors: green, control group; dark blue, low-dose
group; light blue, middle-dose group; red, high-dose group
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123trend was observed. All high dose samples and especially
the 96 h samples differed from the other samples. The
signiﬁcant separation of the high dose group from the others
after 96 h indicates that the interaction effect mainly
occurred 96 h after dose and mainly affects the high dose
group (the separation of low and middle dose from control
groups is small). Still, the samples were arranged along the
PC1 axis according to high dose, middle dose, low dose and
control group. For the 24 h and 48 h samples, separation of
the high-dose group from the other groups was clear and
larger than for the difference between high dose and other
groups at -24 h (i.e. prior administration). These results
show, unlike the linear model of dose and time effect, the
effect of interaction of dose and time is most pronounced for
the high dose group and the last time points (96 h after
administration). In summary, differences between dose
groups and time point found with the interaction
‘dose 9 time’ model were rather comparable to those
which were obtained with the PCA model, but were more
clearly visualized.
3.4 Biomarkers identiﬁcation
With PCA data were visualized by plotting the PC scores
where each point in the scores plot represents an individual
sample and the PC loadings where each point represents one
mass/retention time pair. Thus, the loadings plot gives an
indication of the metabolites that most strongly inﬂuence
the patterns in the scores plot. From the PCA loading plots,
various metabolites could be identiﬁed as being responsible
for the separation between control and different dose
groups, and were therefore viewed as potential biomarkers.
Two datasets were constructed in this study (see Sect. 2.6,
i.e. 0.5–14 min and 0.5–18 min) and subjected to PCA
analysis to screen possible biomarkers. The biomarkers
screened from the two datasets complemented each other
and 34 peaks were assigned as possible biomarkers. A
Student’s t-test, was conducted whether signiﬁcant changes
were observed for these metabolites at various time points
and various doses compared to the control group, and the
metabolites for which the assigned identity could be con-
ﬁrmed with reference standards were listed in Table 2. The
identiﬁcation of these metabolites was achieved according
to the following general procedure: (i) identiﬁcation of the
elemental composition by high resolution mass spectrom-
etry (LC-TOF-MS or LC-LTQ-FTMS), (ii) database search
for known metabolites for obtained elemental composition,
(iii) elimination of certain candidates obtained from the
library using the information obtained from MS/MS spectra
and (iv) inclusion of retention time information. Actually, it
has to be taken into account that the metabolite can be a
conjugate, which is often not included in databases yet. For
many elemental compositions a huge number of possible
Fig. 3 Factor ‘dose’ (a), ‘time’ (b) and interaction ‘dose 9 time’
model (c) scores on the ﬁrst principal component of the corresponding
submodels. Assignment of the colors: green, control group; dark blue,
low-dose group; light blue, middle-dose group; red, high-dose group
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123candidates can be found, and the proper candidate has to be
identiﬁed, by rejecting possible, but not correct candidates.
If the metabolite is not found in any database or all candi-
dates were rejected, and if the metabolite is not a conjugate,
fractionation and enrichment for NMR analysis is a good
option. However, NMR analysis is often not sensitive
enough for metabolites at low concentrations and if the
amount of sample is limited (Rezzi et al. 2008). If the
metabolite is a conjugate, fractionation and hydrolysis is an
option, with subsequent LC-MS/MS analysis. In the ﬁnal
step, the assigned identity of the metabolite should be
conﬁrmed by the analysis of a reference compound if
available; in this manner the identity of uric acid, trypto-
phan, phenylalanine, hippuric acid and cholic acid (see
Table 2) was conﬁrmed. We will discuss below two typical
challenges we encountered during the identiﬁcation proce-
dure, i.e. the identiﬁcation of the quasi-molecular ion in a
complex mass spectrum and the identiﬁcation of a bio-
marker being a conjugate or modiﬁed by biotransformation.
Though ESI is a relative soft ionization method, several
dozen m/z ratios may be recorded for a single chromato-
graphic peak. These ions may be different metabolites, in-
source fragmentation products (Lafaye et al. 2003)o r
various adducts. As an example, peaks with m/z 355.2 and
373.2 at a retention time of 16.7 min increased signiﬁ-
cantly at 96 h after dosing (Fig. 1f). Many masses were
observed in the mass spectrum including m/z 355.2, 373.2,
431.2, 817.4, 839.4, etc. Obtaining the proper quasi-
molecular ion information is critical. Actually, a negative
ion mode MS analysis in the same chromatography con-
dition was helpful to provide complementary information:
in negative ion mode, the mass spectrum of the peak with a
retention time of 16.7 showed major ions at m/z 407.2 and
815.4, which may correspond to [M - H]
- and [2M -
H]
-, respectively. These results suggest that the molecular
mass of the biomarker should be 408.2. Actually no
[M ? H]
? ion was detected in positive mode, and the
masses acquired in positive mode were assigned as follows:
m/z 355.2, 373.2 were in source fragments, and m/z 431.2,
817.4 and 839.4 were [M ? Na]
?, [2M ? H]
? and
[2M ? Na]
?, respectively.
Often, biotransformed conjugates of metabolites are not
present in databases. Such metabolites usually have typical
neutral losses, such as the loss of 176 for glucuronic acid
conjugate. In this study, a signiﬁcant (with regards to
occurrence in different groups and time points) metabolite
with m/z 338.1 at a retention time of 7.16 min was an
interesting biomarker with the neutral loss of 176 (Fig. 4),
suggesting that the metabolite might be a glucuronic acid
conjugate. As no possible glucuronic acid conjugate can-
didate could be found in the database for that nominal mass
(Pubchem compound, http://www.ncbi.nlm.nih.gov/sites/
entrez), the elemental composition of the molecular ion
and characteristic fragments ions were determined by
accurate mass determination with FTMS. The loss of
176.0320 corresponded indeed to the loss of glucuronic
acid. The elemental composition obtained for the uncon-
jugated metabolite was C9H7NO2. Next, a hydrolysis
Table 2 Summary of DOX-induced urinary biomarkers changes at post-dose time-points (hour), following different doses of DOX adminis-
tration (low, middle, high)
Biomarkers Change of biomarker compared to control
for different time-points and doses
d (mg/kg)
24 h 48 h 96 h
Assignment tR (min) Accurate mass
c
of [M ? H]
?
Theoretical
mass (m/z)
Error (ppm) 5 10 20 5 10 20 5 10 20
Uric acid 1.56 169.0356 169.0365 5 – – : –– : – : –
Tryptophan 5.37 205.0972 205.0984 6 – – – – – – – – :
Phenylalanine 3.69 166.0863 166.0852 -6 – ––– ––– –:
Hippuric acid 6.62 180.0655 180.0653 -2 ; ;;; ;;; ;;
Cholic acid
a 16.75 373.2737 373.2751 4 – – – – – – – ::
16.75 355.2632 355.2641 3 – – – – – – – ::
QGAC
b 7.16 338.0870 338.0870 -0.2 – ;;– ;;; ;;
: above control levels; ; below control levels (P\0.05, n = 5); – No signiﬁcant change
a The [M ? H]
? of cholic acid is undetectable with above mentioned UPLC-TOF-MS parameters, m/z 373.2 and 355.2 are the fragments of
cholic acid
b The accurate mass of QGAC (2,8-quinolinediol glucuronic acid) is determined by FTMS
c As determined with TOF except for QGAC
d Control samples of corresponding time point
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123reaction with ß-glucuronidase of the appropriate fraction of
the HPLC separation was carried out, and the obtained
sample analyzed with HPLC-MS. A new peak with m/z
162.1 showed up eluting later than the conjugated metab-
olite, which actually is expected for a glucuronic acid
conjugate. The number of candidate compounds with a
formula of C9H7NO2 was found to be 179 with Pubmed.
MS
3 analysis of this glucuronic acid conjugate was per-
formed and the loss of m/z 18 (162–144), m/z 46 (162–
116), m/z 28 (144–116) and m/z 27 (116–89) indicated that
this compound might contain a COOH group or one CO
and one OH group. Next, by calculation of the degree of
unsaturation (the double bond equivalent is 7), this com-
pound might have a heterocyclic aromatic ring. In addition,
the background information of the samples was taken into
account, i.e. that this compound should be an endogenous
metabolite from rat or a natural compound from food. By
applying these criteria’s, potential candidates are reduced
to two groups, one group were indole carboxylic acids
including indole-2-carboxylic acid, indole-3-carboxylic
acid, indole-5-carboxylic acid etc., another group were
quinoline derivatives including quinoline-3,4-diol, 2,8-
quinolinediol etc. For distinguishing these two groups, a
negative MS/MS was helpful, as indole carboxylic acids
have a typical –COOH group and will produce a signiﬁcant
loss of –COO (with m/z 44) peak (as conﬁrmed by analysis
of carboxylic acid standards). As the hydrolyzed biomarker
did not show this typical mass peak, the potential candi-
dates were reduced to quinoline derivatives. Finally, by
comparing retention time and MS/MS ﬁngerprint, this
biotransformed metabolite was identiﬁed as 2,8-quino-
linediol glucuronic acid conjugate (QGAC).
3.5 Biological interpretation
Table 2 lists the identiﬁed metabolites which endogenous
levels have been altered as a consequence of DOX treat-
ment. The metabolites might be considered as potential
markers of DOX induced toxicity. For the biological con-
nection between these metabolites and DOX toxicity a
network was constructed using Metacore (Fig. 5). Except
for 2,8-quinolinediol glucuronic acid (QGAC), all metab-
olites were present in the Metacore database (including
DOX). It was found that all metabolites associated with the
toxic effects of DOX could be linked to each other within
four steps, i.e. a known biological connection was there
between the metabolites associated with the toxic effects of
DOX. However, in the network most compounds were
linked to each other with four steps, except for phenylal-
anine and tryptophan (2 steps). In most cases the connec-
tors were transport proteins with a broad speciﬁcity. In
conclusion, the biological link in most cases was not very
speciﬁc and cannot be seen as a strong biological con-
nection. However, this ﬁnding is not completely surprising,
as the biological interpretation is based on existing
knowledge and is limited to the data of the database and the
collection of the data; most data have been collected from
different species and are thus not organism-speciﬁc
(Bugrim et al. 2004). Furthermore, the biocomplexity of
mammalian also makes direct connection of dynamic
changed biomarkers difﬁcult, highly complex animals can
be considered ‘superorganisms’ with an internal ecosystem
of diverse symbiotic microbiota and parasites that have
interactive metabolic processes (Nicholson et al. 2004).
Only with a systems toxicology approach, these indirect
biomarkers can be identiﬁed. For example, QGAC is not in
the database and shows a decreasing trend after dosing.
2,8-Quinolinediol has been reported as a metabolite in rat
urine after being fed a diet containing corn but could not be
isolated form corn; it was speculated that it must be formed
from a precursor present in the corn (Inagami et al.1965). It
was also reported that 2,8-quinolinediol could be trans-
formed from quinoline by bacteria(Shukla 1986), which
may suggest that 2,8-quinolinediol and QGAC could be
derived from food and undergo biotransformation by gut
microbiota or by mammalian tissues.
The biological function of the individual biomarkers
may provide some clues for the understanding of DOX
induced toxicity. From 24 h to 48 h after administration,
drug induced toxicity disturbs the metabolism of the
organism and causes a metabolic deviation from homeo-
stasis. Biomarkers at this stage reﬂect the subtle dysfunc-
tion or adaptive response. Hippuric acid, QGAC and uric
acid may be used to characterize the toxicity. Actually, in
toxicity studies a decrease in urinary hippurate is often
observed (Keun 2006). In rat hippurate is synthesized from
Fig. 4 Scheme for the identiﬁcation of a biotransformed biomarker,
i.e. 2,8-quinolinediol glucuronic acid (QGAC) (m/z 338.0870), using
LC-LTQ-FTMS, LC-Q-TOF, MS
2–3 experiments, and fractionation
with subsequent hydrolysis experiments
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123benzoate and glycine by liver mitochondria and the path-
way from benzoate to hippurate may reﬂect hepatic mito-
chondrial dysfunction induced by DOX (Gatley and
Sherratt 1977; Berthiaume and Wallace 2007); also, gut
microbial metabolism and diet can affect the levels of
hippurate in urine (Nicholls et al. 2003; Wang et al. 2005).
The possible reasons for the decrease may be due to dif-
ferent factors including the toxin having an antibiotic effect
which may reduce urinary hippurate by suppressing gut
microﬂora, or the toxin can compete with transport into the
proximal tubular cells (Halligan et al. 1995). DOX lacked
appreciable antibacterial activities (Adrien Bodet et al.
1985). Plausible reasons for the decreased hippurate could
be the binding of DOX to the inner mitochondria mem-
brane resulting in mitochondrial lesions and reduction of
the synthesis of hippuric acid (Goormaghtigh et al. 1990),
or the effects of DOX induced reactive oxygen species
(ROS) on mitochondria(Berthiaume and Wallace 2007).
Uric acid is another sensitive and early biomarker for
monitoring the drug toxicity. Other researchers also found
elevated uric acid concentrations in plasma when high
doses of DOX were given to rat (O ¨z and _ Ilhan 2006).
Systemic administration of uric acid is known to increase
serum antioxidant capacity and it can reduce oxidative
stress (Waring et al. 2001; Waring et al. 2003). The
increased level in bioﬂuid could be useful to eliminate ROS
and can reduce the toxicity of DOX. The QGAC has been
reported as a peroxisome proliferator-activated receptor a-
related biomarker (Zhen et al. 2007), the decrease of this
compound may indicate the effect of ROS on the peroxi-
some (Dewald et al. 2005).
The characteristics of toxicity at 96 h point to an irre-
versible cell death and severe organ lesions. The increase
of tryptophan and phenylalanine in urine has been found in
d-serine-induced nephrotoxicity and were considered as
nephrotoxicity biomarkers (Williams et al. 2005) and
indicated the dysfunction of kidney. Cholic acid is one of
bile acids derived from cholesterol, primarily in the liver,
through three main pathways involving different enzymes
(Bjo ¨rkhem and Eggertsen 2001) and can be used as a
marker of liver dysfunction. Administration of compounds
known to speciﬁcally cause damages to the biliary system
Fig. 5 Network of potential biomarkers induced by the toxicity of DOX
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123in the liver can result in an increase of bile acid in urine
(Beckwith-Hall et al. 1998). In this study, at 96 h post
dose, cholic acid increased signiﬁcant for high and middle
dose group. Even for low dose group, three animals showed
a high level of cholic acid. This result indicates that DOX
can induce liver damage.
4 Conclusions
An UPLC-MS based metabolomics approach was used to
investigate the toxicity induced by DOX in a rat model.
Signiﬁcant dose and time dependent changes were found in
the UPLC-MS urine metabolite proﬁles. With the PCA
model, two major systemic metabolic changes with time, or
metabolic trajectories, could be found for the development
of the toxicity induced by DOX. ASCA allowed separating
the original dataset into submodels to interpret the systemic
effects derived from dose, time and their interactions.
Some possible exploratory early toxicity biomarkers due to
DOX were found. In conclusion, the proposed systems
toxicity approach based on metabolomic proﬁling was able
to reveal novel information in the toxicity of DOX. In
addition, detection of systemic toxic effects by metabolo-
mics appeared to be more sensitive, i.e. detection was
possible at a more early stage, compared with clinical
chemistry and histopathological assessment.
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